Skip to main content

Table 2 Results of the Cox regression analysis evaluating the breast cancer-specific survival (BCSS) and overall survival (OS) of patients with invasive ductal carcinoma (IDC)

From: A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

 

IDC (n = 14,547)

 

BCSSHR (95% CI)

P-value

OS HR (95% CI)

P-value

Age

    

<50

1

 

1

 

50≤

1.060 (0.929 to 1210)

0.386

1.067 (0.944 to 1.206)

0.302

Surgery

    

mastectomy

1

 

1

 

breast conserving surgery

1.049 (0.937 to 1.175)

0.405

1.08 (0.906 to 1.121)

0.882

Tumor size

    

T ≤ 2 cm

1

 

1

 

2 cm < T ≤ 5 cm

1.228 (1.101 to 1.369)

<0.001

1.233 (1.112 to 1.366)

<0.001

5 cm < T

1.434 (1.218 to 1.689)

<0.001

1.395 (1.192 to 1.632)

<0.001

Nodal status

    

0

1

 

1

 

1 to 3

1.045 (0.919 to 1.189)

0.501

1.043 (0.926 to 1.174)

0.488

4 to 9

0.940 (0.679 to 1.302)

0.710

0.903 (0.662 to 1.233)

0.522

10≤

1.018 (0.734 to 1.412)

0.916

0.951 (0.695 to 1.30)

0752

TNMstage

    

stage I

1

 

1

 

stage II

1.090 (0.949 to 1.253)

0.223

1.018 (0.897 to 1.155)

0.784

stage III

1.563 (1.344 to 1.818)

<0.001

1.392 (1.211 to 1.601)

<0.001

Molecular subtype

    

luminal A

1

 

1

 

luminal B

1.175 (1.022 to 1.350)

0.023

1.182 (1.039 to 1.344)

0.011

HER2-overexpression

1.426 (1.200 to 1.695)

<0.001

1.406 (1.201 to 1.646)

<0.001

Triple negative

2.523 (2.160 to 2.948)

<0.001

2.219 (1.924 to 2.559)

<0.001

Lymphatic invasion

    

no

1

 

1

 

yes

4.206 (3.748 to 4.721)

<0.001

3.212 (2.899 to 3.559)

<0.001

Vascular invasion

    

no

1

 

1

 

yes

3.019 (2.747 to 3.317)

<0.001

2.777 (2.540 to 3.036)

<0.001

Estrogen receptor status

    

negative

1

 

1

 

positive

0.736 (0.633 to 0.857)

<0.001

0.671 (0.585 to 0.771)

<0.001

Progesterone receptor status

    

negative

1

 

1

 

positive

0.960 (0.826 to 1.117)

0.600

0.993 (0.861 to 1.146)

0.928

HER2

    

negative

1

 

1

 

positive

1.426 (1.200 to 1.695)

<0.001

1.401 (1.197 to 1.640)

<0.001

Radiation therapy

    

no

1

 

1

 

yes

1.012 (0.911 to 1.124)

0.826

1.010 (0.915 to 1.116)

0.841

Chemotherapy

    

no

1

 

1

 

yes

1.059 (0.895 to 1.252)

0.506

1.113 (0.958 to 1.295)

0.162

Hormonal therapy

    

no

1

 

1

 

yes

1.025 (0.914 to 1.149)

0.671

1.007 (0.905 to 1.121)

0.894

  1. BCSS, breast cancer specific survival; HER2. human epidermal growth 2;HR, hazard ratio; IDC, invasive ductal carcinoma; OS, overall survival.